Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370307 | 0.86 | SLC1A3 (0.43) | SLC1A3HSD17B10WEE1GRIA1GRIA2 | |
| SCHEMBL31276733 | 0.70 | CYP3A4 (0.45) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL22775034 | 0.69 | CYP3A4 (0.47) | SLC1A3HPGDHSD17B10KMOMEN1 | |
| SCHEMBL29604301 | 0.69 | CYP3A4 (0.47) | SLC1A3HPGDHSD17B10KMOMEN1 | |
| SCHEMBL11035167 | 0.69 | MCL1 (0.50) | — | |
| SCHEMBL31754299 | 0.68 | SLC7A5 (0.45) | SLC1A3HPGDHSD17B10KMOMEN1 | |
| SCHEMBL31276230 | 0.67 | HSD17B10 (0.45) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL8824882 | 0.64 | SLC1A3 (0.51) | SLC1A3HSD17B10GRIA1GRIA2GRIA3 | |
| SCHEMBL22775364 | 0.64 | GRIA2 (0.51) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL28560 | 0.64 | SLC1A3 (0.51) | SLC1A3HSD17B10GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | SLC1A3 184/4885HPGD 3877/4885HTT 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.